{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.8","upperLimit":"39.1","value":"26.2"},{"groupId":"OG001","lowerLimit":"10.2","upperLimit":"32.4","value":"19.6"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG003","lowerLimit":"2.3","upperLimit":"51.8","value":"18.2"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.5","upperLimit":"42.6","value":"29.5"},{"groupId":"OG001","lowerLimit":"18.8","upperLimit":"44.1","value":"30.4"},{"groupId":"OG002","lowerLimit":"5.3","upperLimit":"85.3","value":"40.0"},{"groupId":"OG003","lowerLimit":"23.4","upperLimit":"83.3","value":"54.5"}]}],"title":"Marrow Complete Response (mCR)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"9.6","value":"1.8"},{"groupId":"OG002","lowerLimit":"0.5","upperLimit":"71.6","value":"20.0"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"title":"HI: Erythroid Response (HI-E)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"11.3","value":"3.3"},{"groupId":"OG001","lowerLimit":"3.0","upperLimit":"19.6","value":"8.9"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"title":"HI: Platelet Response (HI-P)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG003","lowerLimit":"0.2","upperLimit":"41.3","value":"9.1"}]}],"title":"HI: Neutrophil Response (HI-N)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"11"}],"units":"Participants"}],"description":"CR: normal peripheral, persistent granulocyte count ≥1.0x10\\^9/liter(L), platelet ≥100x10\\^9/L, Hemoglobin (Hgb) ≥11g/dL, normal bone marrow with persistent marrow blasts ≤5%. mCR: reduction of bone marrow blasts to≤5%, decrease by 50% or more with/without normalization of peripheral counts.PR: normal peripheral counts, granulocyte count ≥1.0x10\\^9/L, platelet count ≥100x10\\^9/L, Hgb ≥11 g/dL, normal bone marrow, marrow blasts \\>5%, reduced by 50% or more for at least 4 weeks. HI: HI-E: Hb increase ≥1.5 g/dL in absence of RBC transfusions. HI-P: Absolute increase of platelet count from \\<20 to \\>20X10\\^9/L by at least 100%,if more than 20x10\\^9/L, by absolute increase of at least 30x10\\^9/L in absence of platelet transfusions. HI-N: granulocyte increase ≥100%, by an absolute increase ≥0.5x10\\^9/L for at least 8 weeks. Percentage of participants with CR, mCR, PR, and HI based on IWG 2003 MDS response criteria are reported. Response has been reported based on participants with MDS or CMML.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with MDS received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.","id":"OG000","title":"MDS: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727"},{"description":"Participants with MDS received IV infusion of decitabine 20 mg/m\\^2, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days) followed by ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.","id":"OG001","title":"MDS: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727"},{"description":"Participants with CMML received ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days), followed by IV infusion of decitabine 20 mg/m\\^2, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.","id":"OG002","title":"CMML: Sequence A: First ASTX727, Then IV Decitabine, Then ASTX727"},{"description":"Participants with CMML received IV infusion of decitabine 20 mg/m\\^2, once daily, on Days 1 to 5 in cycle 1 (each cycle = 28 days) followed by ASTX727 tablet, containing the fixed-dose combination of 35 mg decitabine and 100 mg cedazuridine, orally, once daily, on Days 1 to 5 in cycle 2. A washout period of 23 days was maintained between the 2 cycles. From cycle 3, all participants enrolled in cycles 1 and 2 received ASTX727 tablet, once daily, on Days 1 to 5 of each 28-day cycle until disease progression, unacceptable toxicity, treatment discontinuation for other reasons, or withdrawal from the study.","id":"OG003","title":"CMML: Sequence B: First IV Decitabine, Then ASTX727, Then ASTX727"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Set included all participants who received any amount of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 2.7 years","title":"MDS/CMML: Percentage of Participants With Complete Response (CR), Marrow CR (mCR), Partial Response (PR), Hematologic Improvement (HI) Based on International Working Group (IWG) 2006 Myelodysplastic Syndromes (MDS) Response Criteria","type":"SECONDARY","unitOfMeasure":"percentage of participants"}